Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize market dynamics, broaden investor appeal, […]